Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Bullock

Showing results (121-130 of 220) with videos related to

Pageof 22
Sort By:
Oncogene|March 12, 2013
Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinomaX Xie, L Piao, B N Bullock, et al.
The EMBO Journal|June 21, 2008
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylationSonja Baumli, Graziano Lolli, Edward D Lowe, et al.
Bone|November 4, 2010
A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to dateCelia L Gregson, Peter Hollingworth, Martin Williams, et al.
Oncoimmunology|December 22, 2016
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcomeJoseph M Obeid, Gulsun Erdag, Mark E Smolkin, et al.
The Biochemical Journal|October 26, 2019
Lessons from LIMK1 enzymology and their impact on inhibitor designEidarus Salah, Deep Chatterjee, Alessandra Beltrami, et al.
The Journal of Biological Chemistry|March 7, 2007
Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressorAlexandra Grosfeld, Ineke P Stolze, Matthew E Cockman, et al.
Journal of Medicinal Chemistry|August 8, 2014
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutantsAgustin H Mohedas, You Wang, Caroline E Sanvitale, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Thermodynamic stability of wild-type and mutant p53 core domainA N Bullock, J Henckel, B S DeDecker, et al.
Journal of Medicinal Chemistry|December 6, 2011
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modesKilian Huber, Laurent Brault, Oleg Fedorov, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2012
The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structureCassandra J Adams, Ashley C W Pike, Sandra Maniam, et al.
Pageof 22

Showing results (121-130 of 220) with videos related to

Sort By:
Pageof 22
Oncogene|March 12, 2013
Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinomaX Xie, L Piao, B N Bullock, et al.
The EMBO Journal|June 21, 2008
The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylationSonja Baumli, Graziano Lolli, Edward D Lowe, et al.
Bone|November 4, 2010
A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to dateCelia L Gregson, Peter Hollingworth, Martin Williams, et al.
Oncoimmunology|December 22, 2016
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcomeJoseph M Obeid, Gulsun Erdag, Mark E Smolkin, et al.
The Biochemical Journal|October 26, 2019
Lessons from LIMK1 enzymology and their impact on inhibitor designEidarus Salah, Deep Chatterjee, Alessandra Beltrami, et al.
The Journal of Biological Chemistry|March 7, 2007
Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressorAlexandra Grosfeld, Ineke P Stolze, Matthew E Cockman, et al.
Journal of Medicinal Chemistry|August 8, 2014
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutantsAgustin H Mohedas, You Wang, Caroline E Sanvitale, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Thermodynamic stability of wild-type and mutant p53 core domainA N Bullock, J Henckel, B S DeDecker, et al.
Journal of Medicinal Chemistry|December 6, 2011
7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modesKilian Huber, Laurent Brault, Oleg Fedorov, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2012
The p53 cofactor Strap exhibits an unexpected TPR motif and oligonucleotide-binding (OB)-fold structureCassandra J Adams, Ashley C W Pike, Sandra Maniam, et al.
Pageof 22